2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack

Abstract

Ischemic stroke and transient ischemic attack (TIA) are the most common cerebrovascular disorder and leading cause of death in China. The Effective secondary prevention is the vital strategy for reducing stroke recurrence. The aim of this guideline is to provide the most updated evidence-based recommendation to clinical physicians from the prior version. Control of risk factors, intervention for vascular stenosis/occlusion, antithrombotic therapy for cardioembolism, and antiplatelet therapy for noncardioembolic stroke are all recommended, and the prevention of recurrent stroke in a variety of uncommon causes and subtype provided as well. We modified the level of evidence and recommendation according to part of results from domestic RCT in order to facility the clinical practice.

Keywords

Stroke Chinese neurology secondary prevention transient ischemic attack recommendations

Get full access to this article

View all access options for this article.

References

Wang

Cui

. The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke 2011; 6: 355–361.

Wang

Zhao

. Association of hypertension with stroke recurrence depends on ischemic stroke subtype. Stroke 2013; 44: 1232–1237.

The Chinses Society of Neurology. Guidelines for secondary prevention of ischemic stroke and transient ischemic attack in China, 2010. Chin J Neurol 2010; 43: 154–160.

Lovett

Coull

Rothwell

. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62: 569–573.

Kaplan

Tirschwell

Longstreth

Jr . Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. Neurology 2005; 65: 835–842.

Dhamoon

Tai

Boden-Albala

. Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke 2007; 38: 1752–1758.

Wang

Zhang

Wang

Liu

Wang

. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens 2014; 27: 1355–1361.

Group

. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 1995; 108: 710–717.

Group

. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041.

10.

Liu

Wang

Gong

. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res 2009; 32: 1032–1040.

11.

James

Oparil

Carter

. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507–520.

12.

Kernan

Ovbiagele

Black

. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160–2236.

13.

Pergola

White

Szychowski

. Achieved blood pressures in the secondary prevention of small subcortical strokes (SPS3) study: challenges and lessons learned. Am J Hypertens 2014; 27: 1052–1060.

14.

Chimowitz

Lynn

Derdeyn

. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365: 993–1003.

15.

Forster

Szabo

Hennerici

. Pathophysiological concepts of stroke in hemodynamic risk zones–do hypoperfusion and embolism interact? Nat Clin Pract Neurol 2008; 4: 216–225.

16.

Zhang

. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA 2014; 311: 479–489.

17.

Amarenco

Bogousslavsky

Callahan

III . High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–559.

18.

Goldstein

Amarenco

Lamonte

. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 2008; 39: 2444–2448.

19.

Sillesen

Amarenco

Hennerici

. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2008; 39: 3297–3302.

20.

Amarenco

Benavente

Goldstein

. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 2009; 40: 1405–1409.

21.

Amarenco

Goldstein

Callahan

III . Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis 2009; 204: 515–520.

22.

Chaturvedi

Zivin

Breazna

. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology 2009; 72: 688–694.

23.

Callahan

Amarenco

Goldstein

. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol 2011; 68: 1245–1251.

24.

Putaala

Haapaniemi

Kaste

Tatlisumak

. Statins after ischemic stroke of undetermined etiology in young adults. Neurology 2011; 77: 426–430.

25.

Stone

Robinson

Lichtenstein

. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(25 Suppl 2): S1–45.

26.

Flint

Conell

Rao

. Effect of statin use during hospitalization for intracerebral hemorrhage on mortality and discharge disposition. JAMA Neurol 2014; 71: 1364–1371.

27.

Pan

Jing

Wang

. Use of statin during hospitalization improves the outcome after intracerebral hemorrhage. CNS Neurosci Ther 2014; 20: 548–555.

28.

Ivey

Ryan

Hafer-Macko

. High prevalence of abnormal glucose metabolism and poor sensitivity of fasting plasma glucose in the chronic phase of stroke. Cerebrovasc Dis 2006; 22: 368–371.

29.

Jia

Zhao

Wang

. Diabetes and poor outcomes within 6 months after acute ischemic stroke: the China National Stroke Registry. Stroke 2011; 42: 2758–2762.

30.

Matz

Keresztes

Tatschl

. Disorders of glucose metabolism in acute stroke patients: an underrecognized problem. Diabetes Care 2006; 29: 792–797.

31.

Jia

Zheng

Zhao

. Abnormal glucose regulation in patients with acute stroke across China: prevalence and baseline patient characteristics. Stroke 2012; 43: 650–657.

32.

Hier

Foulkes

Swiontoniowski

. Stroke recurrence within 2 years after ischemic infarction. Stroke 1991; 22: 155–161.

33.

Zhang

Wang

. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371: 1783–1789.

34.

Zhang

Wang

. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2014; 2: 474–480.

35.

Knowler

Barrett-Connor

Fowler

. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.

36.

Advance Collaborative Group. Patel

MacMahon

. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572.

37.

Kelly

Bazzano

Fonseca

Tatlisumak

. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151: 394–403.

38.

Ray

Seshasai

Wijesuriya

. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765–1772.

39.

Wilcox

Bousser

Betteridge

. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865–873.

40.

Farmer

Wade

French

. Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial. Health Technol Assess 2009; 13: iii–iv, ix–xi, 1–50. .

41.

Control

Turnbull

Abraira

. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288–2298.

42.

American Diabetes Association. Standards of medical care in diabetes–2013. Diabetes Care 2013; 36: S11–S66.

43.

Buse

Ginsberg

Bakris

. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162–172.

44.

Wolf

D’Agostino

Kannel

Bonita

Belanger

. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988; 259: 1025–1029.

45.

Shinton

Beevers

. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989; 298: 789–794.

46.

Howard

Wagenknecht

Cai

Cooper

Kraut

Tool

. Cigarette smoking and other risk factors for silent cerebral infarction in the general population. Stroke 1998; 29: 913–917.

47.

Iribarren

Darbinian

Klatsky

Friedman

. Cohort study of exposure to environmental tobacco smoke and risk of first ischemic stroke and transient ischemic attack. Neuroepidemiology 2004; 23: 38–44.

48.

Lam

Jiang

. Passive smoking and risk of peripheral arterial disease and ischemic stroke in Chinese women who never smoked. Circulation 2008; 118: 1535–1540.

49.

Oono

Mackay

Pell

. Meta-analysis of the association between secondhand smoke exposure and stroke. J Public Health (Oxf) 2011; 33: 496–502.

50.

Zhang

Shu

Yang

. Association of passive smoking by husbands with prevalence of stroke among Chinese women nonsmokers. Am J Epidemiol 2005; 161: 213–218.

51.

Kawachi

Colditz

Stampfer

. Smoking cessation and decreased risk of stroke in women. JAMA 1993; 269: 232–236.

52.

Wannamethee

Shaper

Whincup

Walker

. Smoking cessation and the risk of stroke in middle-aged men. JAMA 1995; 274: 155–160.

53.

Papadakis

Aitken

Gocan

. A randomised controlled pilot study of standardised counselling and cost-free pharmacotherapy for smoking cessation among stroke and TIA patients. BMJ Open 2011; 1: e000366.

54.

Stead

Lancaster

. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev 2012; 10: CD008286.

55.

Yaggi

Concato

Kernan

Lichtman

Brass

Mohsenin

. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005; 353: 2034–2041.

56.

Marshall

Wong

Cullen

Knuiman

Grunstein

. Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the Busselton Health Study cohort. J Clin Sleep Med 2014; 10: 355–362.

57.

Johnson

. Frequency of sleep apnea in stroke and TIA patients: a meta-analysis. J Clin Sleep Med 2010; 6: 131–137.

58.

Good

Henkle

Gelber

Welsh

Verhulst

. Sleep-disordered breathing and poor functional outcome after stroke. Stroke 1996; 27: 252–259.

59.

Sahlin

Sandberg

Gustafson

. Obstructive sleep apnea is a risk factor for death in patients with stroke: a 10-year follow-up. Arch Intern Med 2008; 168: 297–301.

60.

Kaneko

Hajek

Zivanovic

Raboud

Bradley

. Relationship of sleep apnea to functional capacity and length of hospitalization following stroke. Sleep 2003; 26: 293–297.

61.

Epstein

Kristo

Strollo

Jr . Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5: 263–276.

62.

Giles

Lasserson

Smith

. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006; 19: CD001106.

63.

Parra

Sánchez-Armengol

Bonnin

. Early treatment of obstructive apnoea and stroke outcome: a randomised controlled trial. Eur Respir J 2011; 37: 1128–1136.

64.

Brown

Chervin

Kalbfleisch

. Sleep apnea treatment after stroke (SATS) trial: is it feasible? J Stroke Cerebrovasc Dis 2013; 22: 1216–1224.

65.

Bravata

Concato

Fried

. Continuous positive airway pressure: evaluation of a novel therapy for patients with acute ischemic stroke. Sleep 2011; 34: 1271–1277.

66.

Sandberg

Franklin

Bucht

Eriksson

Gustafson

. Nasal continuous positive airway pressure in stroke patients with sleep apnoea: a randomized treatment study. Eur Respir J 2001; 18: 630–634.

67.

Ryan

Bayley

Green

Murray

Bradley

. Influence of continuous positive airway pressure on outcomes of rehabilitation in stroke patients with obstructive sleep apnea. Stroke 2011; 42: 1062–1067.

68.

Hsu

Vennelle

Engleman

Dennis

Douglas

. Sleep-disordered breathing after stroke: a randomised controlled trial of continuous positive airway pressure. J Neurol Neurosurg Psychiatry 2006; 77: 1143–1149.

69.

Huang

Cheng

. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7: 494–499.

70.

Shinohara

Katayama

Uchiyama

. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959–968.

71.

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323: 1505–1511.

72.

Ezekowitz

Bridgers

James

. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406–1412.

73.

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–1457.

74.

McCormick

Gurwitz

Goldberg

. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001; 161: 2458–2463.

75.

Birman-Deych

Radford

Nilasena

Gage

. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006; 37: 1070–1074.

76.

Wang

Yang

Wang

. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the china national stroke registry. J Stroke Cerebrovasc Dis 2014; 23: 1157–1163.

77.

Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342: 1255–1262.

78.

Lansberg

O’Donnell

Khatri

. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e601S–636S.

79.

Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.

80.

Connolly

Eikelboom

. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011; 155: 579–586.

81.

ACTIVE Writing Group of the ACTIVE Investigators. Connolly

Pogue

. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903–1912.

82.

Connolly

Eikelboom

Joyner

. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817.

83.

Connolly

Ezekowitz

Yusuf

. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.

84.

Giugliano

Ruff

Braunwald

. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–2104.

85.

Granger

Alexander

McMurray

. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992.

86.

Patel

Mahaffey

Garg

. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.

87.

Berge

Abdelnoor

Nakstad

Sandset

. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000; 355: 1205–1210.

88.

Lee

Park

Shin

. Symptomatic hemorrhagic transformation and its predictors in acute ischemic stroke with atrial fibrillation. Eur Neurol 2010; 64: 193–200.

89.

Heidbuchel

Verhamme

Alings

. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625–651.

90.

Verma

Cairns

Mitchell

. 2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol 2014; 30: 1114–1130.

91.

Sandercock

Bamford

Dennis

. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project). BMJ 1992; 305: 1460–1465.

92.

Paciaroni

Agnelli

Caso

. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost 2005; 3: 1218–1223.

93.

Lamassa

Di Carlo

Pracucci

. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001; 32: 392–398.

94.

Marini

De Santis

Sacco

. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36: 1115–1119.

95.

Rizos

Güntner

Jenetzky

. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke 2012; 43: 2689–2694.

96.

Flint

Banki

Ren

Rao

. Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry. Stroke 2012; 43: 2788–2790.

97.

Gladstone

Spring

Dorian

. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014; 370: 2467–2477.

98.

Bonow

Carabello

Chatterjee

. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118: e523–661.

99.

Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology(ESC), European Association for Cardio-Thoracic Surgery(EACTS). Vahanian

. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451–2496.

100.

Whitlock

Sun

Fremes

Rubens

Teoh

. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e576S–e600S.

101.

North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325: 445–453.

102.

MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. European Carotid Surgery Trialists’ Collaborative Group. Lancet 1991; 337: 1235–1243.

103.

Mayberg

Wilson

Yatsu

. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA 1991; 266: 3289–3294.

104.

Howard

Lutsep

Mackey

. Influence of sex on outcomes of stenting versus endarterectomy: a subgroup analysis of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). Lancet Neurol 2011; 10: 530–537.

105.

Brott

Hobson

II Howard

. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363: 11–23.

106.

Hugl

Oldenburg

Neuhauser

Hakaim

. Effect of age and gender on restenosis after carotid endarterectomy. Ann Vasc Surg 2006; 20: 602–608.

107.

Yadav

Wholey

Kuntz

. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004; 351: 1493–1501.

108.

Mas

Chatellier

Beyssen

. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006; 355: 1660–1671.

109.

Eckstein

Ringleb

Allenberg

. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol 2008; 7: 893–902.

110.

International Carotid Stenting Study Investigators. Ederle

Dobson

. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet 2010; 375: 985–997.

111.

Eberhardt

Naegele

Raygrotzki

Weller

Ernemann

. Stenting of vertebrobasilar arteries in symptomatic atherosclerotic disease and acute occlusion: case series and review of the literature. J Vasc Surg 2006; 43: 1145–1154.

112.

Berguer

Morasch

Kline

Kazmers

Friedland

. Cervical reconstruction of the supra-aortic trunks: a 16-year experience. J Vasc Surg 1999; 29: 239–246. discussion 246–238.

113.

Law

Colburn

Moore

Quinones-Baldrich

Machleder

Gelabert

. Carotid-subclavian bypass for brachiocephalic occlusive disease. Choice of conduit and long-term follow-up. Stroke 1995; 26: 1565–1571.

114.

Kasner

Chimowitz

Lynn

. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006; 113: 555–563.

115.

Lyrer

Engelter

. Antithrombotic drugs for carotid artery dissection. Cochrane Database Syst Rev 2010; 10: CD000255.

116.

Kitsios

Dahabreh

Abu Dabrh

Thaler

Kent

. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke 2012; 43: 422–431.

117.

Homma

Sacco

Di Tullio

Thaler

Kent

. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 2625–2631.

118.

Shon

Kim

Thaler

Kent

. Long-term follow-up of incidental intracranial aneurysms in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis 2013; 22: 329–333.

119.

Ishikawa

Hirayama

Nakamura

Ikeda

. Incidental cerebral aneurysms in acute stroke patients: comparison of asymptomatic healthy controls. J Neurol Sci 2010; 298: 42–45.

120.

Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir 2012; 52: 245–266.

121.

Matsushima

Inoue

Suzuki

Fujii

Fukui

Hasuo

. Surgical treatment of moyamoya disease in pediatric patients–comparison between the results of indirect and direct revascularization procedures. Neurosurgery 1992; 31: 401–405.

122.

Mizoi

Kayama

Yoshimoto

Nagamine

. Indirect revascularization for moyamoya disease: is there a beneficial effect for adult patients? Surg Neurol 1996; 45: 541–548. discussion 548–549.

123.

Choi

Kim

Lee

. Natural history of moyamoya disease: comparison of activity of daily living in surgery and non surgery groups. Clin Neurol Neurosurg 1997; 99: S11–18.

124.

Ishikawa

Houkin

Kamiyama

Abe

. Effects of surgical revascularization on outcome of patients with pediatric moyamoya disease. Stroke 1997; 28: 1170–1173.

125.

Al-Shahi Salman

Dennis

. Antiplatelet therapy may be continued after intracerebral hemorrhage. Stroke 2014; 45: 3149–3150.

126.

Chong

Chan

Pong

. Use of aspirin in Chinese after recovery from primary intracranial haemorrhage. Thromb Haemost 2012; 107: 241–247.

127.

Pessin

Estol

Lafranchise

Caplan

. Safety of anticoagulation after hemorrhagic infarction. Neurology 1993; 43: 1298–1303.

128.

Brown

Bussell

. Medication adherence: WHO cares? Mayo Clin Proc 2011; 86: 304–314.

129.

Glader

Sjolander

Eriksson

Lundberg

. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010; 41: 397–401.

130.

Bushnell

Olson

Zhao

. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology 2011; 77: 1182–1190.

131.

Liu

Shen

. Persistence of secondary prevention medications after acute ischemic stroke or transient ischemic attack in Chinese population: data from China National Stroke Registry. Neurol Res 2013; 35: 29–36.

132.

Wang

. Persistence with antihypertensive agents for 12 months after ischemic stroke reduces the rates of death and dependency. CNS Neurosci Ther 2013; 19: 142–144.

133.

Bushnell

Zimmer

Pan

. Persistence with stroke prevention medications 3 months after hospitalization. Arch Neurol 2010; 67: 1456–1463.

134.

Peng

Anderson

. Implementation of a structured guideline-based program for the secondary prevention of ischemic stroke in China. Stroke 2014; 45: 515–519.

135.

Madonna

de Stefano

Coppola

. Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 2002; 33: 51–56.

136.

Wald

Law

Morris

. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202.

137.

Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015–2022.

138.

Holmes

Newcombe

Hubacek

. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011; 378: 584–594.

139.

Lonn

Yusuf

Arnold

. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567–1577.

140.

Spence

Bang

Chambless

Stampfer

. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. Stroke 2005; 36: 2404–2409.

141.

VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 2010; 9: 855–865.

142.

Kennedy

Hill

Ryckborst

Eliasziw

Demchuk

Buchan

. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6: 961–969.

143.

Wang

Zhao

. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369: 11–19.

144.

Wong

Chen

. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010; 9: 489–497.

145.

Bhatt

Fox

Hacke

. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–1717.

146.

Rothwell

Eliasziw

Gutnikov

. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003; 361: 107–116.

147.

Rothwell

Eliasziw

Gutnikov

Warlow

Barnett

. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363: 915–924.

148.

Wang

Bowyer

Warlow

Barnett

. Risk factors for death or stroke after carotid endarterectomy: observations from the Ontario Carotid Endarterectomy Registry. Stroke 2003; 34: 2568–2573.

149.

Brott

Halperin

Abbara

. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. Stroke 2011; 42: e464–540.

150.

Berguer

Flynn

Kline

Caplan

. Surgical reconstruction of the extracranial vertebral artery: management and outcome. J Vasc Surg 2000; 31: 9–18.

151.

Peterson

Resnick

Morasch

Hassoun

Eskandari

. Aortic arch vessel stenting: a single-center experience using cerebral protection. Arch Surg 2006; 141: 560–563. discussion 563–564.

152.

Filippo

Francesco

. Percutaneous angioplasty and stenting of left subclavian artery lesions for the treatment of patients with concomitant vertebral and coronary subclavian steal syndrome. Cardiovasc Intervent Radiol 2006; 29: 348–353.

153.

AbuRahma

Bates

Stone

. Angioplasty and stenting versus carotid-subclavian bypass for the treatment of isolated subclavian artery disease. J Endovasc Ther 2007; 14: 698–704.

154.

van Hattum

de Vries

Lalezari

van den Berg

Moll

. Angioplasty with or without stent placement in the brachiocephalic artery: feasible and durable? A retrospective cohort study. J Vasc Interv Radiol 2007; 18: 1088–1093.

155.

Van Noord

Lin

Cavendish

. Rates of symptom reoccurrence after endovascular therapy in subclavian artery stenosis and prevalence of subclavian artery stenosis prior to coronary artery bypass grafting. Vasc Health Risk Manag 2007; 3: 759–762.

156.

Connors

III Wojak

. Percutaneous transluminal angioplasty for intracranial atherosclerotic lesions: evolution of technique and short-term results. J Neurosurg 1999; 91: 415–423.

157.

SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 2004; 35: 1388–1392.

158.

Marks

Wojak

Al-Ali

. Angioplasty for symptomatic intracranial stenosis: clinical outcome. Stroke 2006; 37: 1016–1020.

159.

Bose

Hartmann

Henkes

. A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study. Stroke 2007; 38: 1531–1537.

160.

Fiorella

Levy

Turk

. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke 2007; 38: 881–887.

161.

Zaidat

Klucznik

Alexander

. The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis. Neurology 2008; 70: 1518–1524.

162.

Siddiq

Memon

Vazquez

Safdar

Qureshi

. Comparison between primary angioplasty and stent placement for symptomatic intracranial atherosclerotic disease: meta-analysis of case series. Neurosurgery 2009; 65: 1024–1033. discussion 1033–1034.

163.

Al-Ali

Cree

Duan

. How effective is endovascular intracranial revascularization in stroke prevention? Results from Borgess Medical Center Intracranial Revascularization Registry. AJNR 2011; 32: 1227–1231.

164.

Jiang

Gao

Cui

. Outcome of patients with ≥70% symptomatic intracranial stenosis after wingspan stenting. Stroke 2011; 42: 1971–1975.

165.

Miao

Jiang

. Randomized controlled trial of symptomatic middle cerebral artery stenosis: endovascular versus medical therapy in a Chinese population. Stroke 2012; 43: 3284–3290.